As the litigation moves forward, we want women to know we are offering free case reviews for those who have suffered pain and other complications following surgery in which transvaginal mesh products were used.
San Diego, CA (PRWEB) July 31, 2014
According to a May 1, 2014 article by the Philadelphia Business Journal, Endo International, one of several manufacturing companies that makes transvaginal mesh products, agreed to settle thousands of transvaginal claims for $830 million (in re: American Medical Systems, Inc., Pelvic Repair Systems Products Liability Litigation (MDL No. 2325). Melinda Helbock, Founder of The Law Office of Melinda J. Helbock A.P.C., said she agrees with the settlement and is pleased to see litigation moving forward.
“We are pleased to see that makers of transvaginal mesh products are beginning to settle claims,” said Melinda Helbock, Founder of The Law Office of Melinda J. Helbock A.P.C. “As the litigation moves forward, we want women to know we are offering free case reviews for those who have suffered pain and other complications following surgery in which transvaginal mesh products were used.”
Transvaginal mesh is used to reinforce weakened vaginal walls in women with pelvic organ prolapse or to provide support for the urethra in women with urinary incontinence.
In October 2008, the FDA issued a safety communication to notify health care providers and patients about serious complications that were associated with transvaginal mesh products. Then, in July 2011, the agency sent a follow up to warn that the risks were “not rare.”*
“Based on an updated analysis of adverse events reported to the FDA and complications described in the scientific literature, the FDA identified surgical mesh for transvaginal repair of POP as an area of continuing serious concern,” the FDA said in the 2011 update. “The FDA is issuing this update to inform you that serious complications associated with surgical mesh for transvaginal repair of POP are not rare.”*
According to the FDA’s safety communication, the agency received more than 1,000 reports of adverse events involving transvaginal mesh from 2005 to 2007 and another 2,874 reports of complications from Jan. 1, 2008 to Dec.31, 2010. The most commonly reported problems, according to the FDA, include mesh erosion, organ perforation, pain, infection, bleeding and urinary problems.
“Even though the FDA recognized possible problems with transvaginal mesh products, they continue to be used,” said Helbock. “We are keeping a close watch on the litigation and are happy with the Endo settlement.”
For more information or to speak with a San Diego personal injury lawyer about a possible transvaginal mesh claim, contact The Law Office of Melinda J. Helbock, A.P.C.